Biotech · Private company · Halethorpe, MD, US

Fzata, Inc.

Track this companyFree. Adds Fzata, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards4

Development of a Dual-Action Oral Immunotherapy for Clostridioides difficile PreventionFiscal year 2026 · $313.1KNIH RePORTER 1R44AI197301-01 · fetched Nov 12, 2026
Gut-Targeted IL-10 Delivery via Engineered Saccharomyces boulardii to Prevent Immune Checkpoint Inhibitor ColitisFiscal year 2026 · $372.2KNIH RePORTER 1R44DK146567-01 · fetched Nov 12, 2026
A novel oral immunotherapy for chronic visceral pain of irritable bowel syndromeFiscal year 2026 · $2.1MNIH RePORTER 4UH3NS135350-02 · fetched Nov 12, 2026
A novel oral immunotherapy for chronic visceral pain of irritable bowel syndromeFiscal year 2024 · $2.1MNIH RePORTER 1UG3NS135350-01A1 · fetched Nov 12, 2026